<DOC>
	<DOCNO>NCT00866840</DOCNO>
	<brief_summary>RATIONALE : Riluzole may stop slow growth tumor cell may effective treatment melanoma . PURPOSE : This phase II trial study well riluzole work treat patient stage III stage IV melanoma remove surgery .</brief_summary>
	<brief_title>Riluzole Treating Patients With Stage III Stage IV Melanoma That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether administration daily dose riluzole result tumor shrinkage , measure RECIST criterion , patient advance melanoma . Secondary - Determine long-term toxicity riluzole administer patient . - Compare survival patient historical control . OUTLINE : Patients receive oral riluzole twice daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant melanoma Unresectable stage III stage IV disease Measurable disease accord RECIST criterion , define ≥ 1 unidimensionally measurable lesion &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan No known brain metastasis unless treat stable ≥ 2 week MRI evaluation PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,000/μL Platelet count ≥ 50,000/μL Total bilirubin ≤ 2 time upper limit normal ( ULN ) AST/ALT ≤ 3 time ULN INR ≤ 1.5 time ULN Not pregnant Negative pregnancy test Fertile patient must use effective contraception 2 week completion study treatment No second primary malignancy , except carcinoma situ cervix , adequately treat nonmelanoma carcinoma skin , malignancy treat ≥ 5 year ago evidence recurrence No concurrent serious systemic disorder ( include active infection ) , opinion investigator , would compromise safety patient compromise patient 's ability complete study No history allergic reaction attribute riluzole No known history hepatitis B C PRIOR CONCURRENT THERAPY : No 1 prior therapeutic chemotherapy regimen advance melanoma Prior treatment riluzole clinical trial CINJ090603 allow No concurrent investigational commercial agent therapy treatment malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>